These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 18695668)

  • 1. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
    Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells.
    D'Orsogna LJ; Wright MP; Krueger RG; McKinnon EJ; Buffery SI; Witt CS; Staples N; Loh R; Cannell PK; Christiansen FT; French MA
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):795-803. PubMed ID: 19539210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
    Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
    Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
    Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT.
    Masjosthusmann K; Ehlert K; Eing BR; Roth J; Koehler G; Juergens H; Fruehwald M; Groll AH
    Bone Marrow Transplant; 2009 May; 43(9):679-84. PubMed ID: 19029962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors.
    Eyrich M; Leiler C; Lang P; Schilbach K; Schumm M; Bader P; Greil J; Klingebiel T; Handgretinger R; Niethammer D; Schlegel PG
    Bone Marrow Transplant; 2003 Aug; 32(4):379-90. PubMed ID: 12900774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
    Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
    Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis.
    Farge D; Henegar C; Carmagnat M; Daneshpouy M; Marjanovic Z; Rabian C; Ilie D; Douay C; Mounier N; Clave E; Bengoufa D; Cabane J; Marolleau JP; Gluckman E; Charron D; Toubert A
    Arthritis Rheum; 2005 May; 52(5):1555-63. PubMed ID: 15880600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
    García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
    Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
    Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
    Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
    Shortt J; Spencer A
    Bone Marrow Transplant; 2006 Sep; 38(6):433-6. PubMed ID: 16892074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT.
    Bühlmann L; Buser AS; Cantoni N; Gerull S; Tichelli A; Gratwohl A; Stern M
    Bone Marrow Transplant; 2011 Oct; 46(10):1357-62. PubMed ID: 21113185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.
    Abdel-Azim H; Elshoury A; Mahadeo KM; Parkman R; Kapoor N
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1437-1446. PubMed ID: 28495643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation.
    Larosa F; Marmier C; Robinet E; Ferrand C; Saas P; Deconinck E; Bulabois CE; Rohrlich PS; Ledu K; Helias P; Tiberghien P; Cahn JY
    Bone Marrow Transplant; 2005 May; 35(9):859-68. PubMed ID: 15765116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.